Your browser doesn't support javascript.
loading
Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy.
Alig, Annabel H S; Heinemann, Volker; Geissler, Michael; Fischer von Weikersthal, Ludwig; Decker, Thomas; Heinrich, Kathrin; Held, Swantje; Weiss, Lena; Fischer, Laura E; Moosmann, Nicolas; Stahler, Arndt; Jelas, Ivan; Kurreck, Annika; von Einem, Jobst C; Reinacher-Schick, Anke C; Tannapfel, Andrea; Giessen-Jung, Clemens; Stintzing, Sebastian; Modest, Dominik P.
Afiliación
  • Alig AHS; Department of Hematology, Oncology, and Tumorimmunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and HumboldtUniversität zu Berlin, 10117 Berlin, Germany.
  • Heinemann V; Department of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universität (LMU), 81377 Munich, Germany.
  • Geissler M; German Cancer Consortium (DKTK), DKFZ, 69120 Heidelberg, Germany.
  • Fischer von Weikersthal L; Hospital Karlsruhe, 76133 Karlsruhe, Germany.
  • Decker T; Klinikum St. Marien, 92224 Amberg, Germany.
  • Heinrich K; Onkologische Praxis, 88212 Ravensburg, Germany.
  • Held S; Department of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universität (LMU), 81377 Munich, Germany.
  • Weiss L; ClinAssess GmbH, 51379 Leverkusen, Germany.
  • Fischer LE; Department of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universität (LMU), 81377 Munich, Germany.
  • Moosmann N; Department of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universität (LMU), 81377 Munich, Germany.
  • Stahler A; Krankenhaus Barmherzige Brüder Regensburg, 93049 Regensburg, Germany.
  • Jelas I; Department of Hematology, Oncology, and Tumorimmunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and HumboldtUniversität zu Berlin, 10117 Berlin, Germany.
  • Kurreck A; Department of Hematology, Oncology, and Tumorimmunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and HumboldtUniversität zu Berlin, 10117 Berlin, Germany.
  • von Einem JC; Department of Hematology, Oncology, and Tumorimmunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and HumboldtUniversität zu Berlin, 10117 Berlin, Germany.
  • Reinacher-Schick AC; Department of Hematology, Oncology, and Tumorimmunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and HumboldtUniversität zu Berlin, 10117 Berlin, Germany.
  • Tannapfel A; St. Josef-Hospital, Klinikum der Ruhr-Universität Bochum, 44791 Bochum, Germany.
  • Giessen-Jung C; Pathologisches Institut der Ruhr Universität Bochum, 44789 Bochum, Germany.
  • Stintzing S; Department of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universität (LMU), 81377 Munich, Germany.
  • Modest DP; Department of Hematology, Oncology, and Tumorimmunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and HumboldtUniversität zu Berlin, 10117 Berlin, Germany.
Cancers (Basel) ; 14(3)2022 Jan 21.
Article en En | MEDLINE | ID: mdl-35158793
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza